Literature DB >> 1423280

Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity.

R Perez-Soler1, A R Khokhar.   

Abstract

cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (NDDP), a lipophilic cisplatin analogue containing two branched leaving groups of 10 carbon atoms, is undergoing clinical evaluation in a liposomal formulation. In previous studies, NDDP entrapped in multilamellar vesicles composed of dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG) at a 7:3 molar ratio was non-nephrotoxic in humans, not cross-resistant with cisplatin in different in vitro and in vivo systems, and more active than cisplatin against murine models of experimental liver metastases whereas free NDDP was devoid of in vivo antitumor activity at the optimal dose of L-NDDP and barely active at higher doses. To elucidate the mechanisms by which the liposomal carrier enhances the biological properties to this class of antitumor agents, we studied the effect of the liposome composition, size of the branched leaving groups of the platinum compound, and pH and composition of the aqueous phase on the entrapment efficiency, drug leakage, drug stability, and in vivo toxicity and antitumor activity of different liposomal formulations of these agents. In experiments using normal saline as aqueous phase, the presence of DMPG in the lipid bilayer resulted in a decreased stability and an increased biological activity of NDDP, whereas NDDP entrapped in liposomes composed of DMPC alone (not containing DMPG) was stable but devoid of antitumor activity. In studies with structurally related analogues with branched leaving groups of 5, 6, 7, and 9 carbon atoms, similar trends were observed. In addition, the number of carbon atoms in the leaving groups was directly and inversely related to the entrapment efficiency and stability of the analogues, respectively, independently of lipid composition; increasing the size of the branched leaving groups resulted in an increased in situ degradation of the platinum compound and enhanced biological activity and potency. These results suggest that this class of platinum compounds exerts its biological activity through the formation of active intermediates in situ within the lipid bilayers and that the activation reaction is highly dependent on the presence of DMPG and the size of the lipophilic leaving group.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1423280

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Nanocarriers for delivery of platinum anticancer drugs.

Authors:  Hardeep S Oberoi; Natalia V Nukolova; Alexander V Kabanov; Tatiana K Bronich
Journal:  Adv Drug Deliv Rev       Date:  2013-10-08       Impact factor: 15.470

Review 2.  Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.

Authors:  V Pinzani; F Bressolle; I J Haug; M Galtier; J P Blayac; P Balmès
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria.

Authors:  P M Furneri; M Fresta; G Puglisi; G Tempera
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

4.  Lipophilic platinum complexes entrapped in liposomes: improved stability and preserved antitumor activity with complexes containing linear alkyl carboxylato leaving groups.

Authors:  R Perez-Soler; I Han; S al-Baker; A R Khokhar
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes.

Authors:  A Mori; S P Wu; I Han; A R Khokhar; R Perez-Soler; L Huang
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

6.  Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye.

Authors:  Jayaganesh V Natarajan; Sujay Chattopadhyay; Marcus Ang; Anastasia Darwitan; Selin Foo; Ma Zhen; Magdalene Koo; Tina T Wong; Subbu S Venkatraman
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

7.  Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye.

Authors:  Jayaganesh V Natarajan; Marcus Ang; Anastasia Darwitan; Sujay Chattopadhyay; Tina T Wong; Subbu S Venkatraman
Journal:  Int J Nanomedicine       Date:  2012-01-05

8.  Liposome formulations for effective administration of lipophilic malonatoplatinum(II) complexes.

Authors:  Insook Han; Mee Sook Jun; Moon Kyu Kim; Jung Chul Kim; Youn Soo Sohn
Journal:  Jpn J Cancer Res       Date:  2002-11

Review 9.  Cisplatin-Membrane Interactions and Their Influence on Platinum Complexes Activity and Toxicity.

Authors:  Nuno Martinho; Tânia C B Santos; Helena F Florindo; Liana C Silva
Journal:  Front Physiol       Date:  2019-01-11       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.